Alopecia Market is estimated to be USD 2.71 billion in 2019 and is predicted to reach USD 6.19 billion by 2030 with a CAGR of 7.8%

Alopecia refers to the excessive hair loss or damage from areas of the body where it generally grows, under certain medical conditions or dietary issues. Ageing and hormonal imbalance, chronic disease like arthritis, cancer, hypertension, and depression also leads to hair loss especially among middle aged population. There are different types of alopecia based on the type of hair loss or the area that is affected namely; Alopecia areata (hair loss in patches), Alopecia totalis (lose all hair on the scalp), and Alopecia universalis (lose all hair on the body).

Scientists say that there is no specific way of predicting the hair loss pattern or how severe or long lasting it can be, however the treatment for hair loss is essential. Recent genetic and preclinical studies have helped in understanding the immune pathogenesis of alopecia. This has contributed towards advanced development of targeted therapies for the treatment of this medical condition. Introduction of targeted therapies has outpaced the conventional therapies which have now become the standard treatment for alopecia.

Access Full Description of this report at:-

https://www.nextmsc.com/report/alopecia-market

Top Companies: Aclaris Therapeutics Inc., Cipla Limited, Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC., HCell Inc., Dr. Reddy’s Laboratories, Johnson & Johnson, Sun Pharma and Histogen, Inc and others.

Market Dynamics and Trends

The incidence and prevalence of alopecia is increasing globally. Changing lifestyles of people such as the increasing consumption of alcohol, tobacco, and other associated products, increasing stress levels, and the rapidly increasing geriatric population are contributing towards the growing prevalence of alopecia. Moreover, increasing consumer disposable incomes and health awareness, emphasis to look good, and technological advancement in hair treatment medical devices are some other key drivers for this market. Since accessibility for scalp treatment is easily available, the demand for alopecia treatment has significantly increased. However, high cost and possible side effects or allergic reactions of the medications are expected to restrain the growth of the Alopecia market.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future. Pfizer received Breakthrough Therapy designation from the USFDA for its in-development investigational oral Janus kinase (JAK3) inhibitor PF-06651600 in September 2018. This new product is expected to be the inhibitor that will aid in the treatment of alopecia areata. In 2017, Perrigo Company PLC, launched over-the-counter Women's Rogaine, which helps to regrow hair on top of the scalp. The launches of such novel products in the market is expected to drive the global alopecia market growth.

Request sample copy of this report at:-

https://www.nextmsc.com/Alopecia-Market/request-sample

Market Segmentations and Scope of the Study:

The alopecia market share is analyzed on the basis of drug type, route of administration, gender, disease type, distribution channel, and geography. On the basis of drug type, the alopecia market is segmented into minoxidil, finasteride, corticosteroids, and other drugs. The route of administration segment is divided into oral, topical, and injectable. On the basis of gender the market is classified into male and female. Type of diseases comprise of alopecia universalis, alopecia areata, alopecia totalis, and others. The distribution channels covers the market for hospital pharmacies, retail pharmacies, and online pharmacies. The geographical segmentation covers North America, Europe, Asia Pacific, and Rest of the World.

Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.